Sara Pressel - Concepedia

Author

Sara Pressel

The University of Texas Health Science Center at Houston

Also Known As

S L Pressel, S PRESSEL, S Pressel, S. PRESSEL, S. Pressel, SARA L. PRESSEL, Sara L Pressel, Sara L. Pressel, Sara Pressel

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Health Science Center at Houston Case Western Reserve University University of Alabama at Birmingham National Heart Lung and Blood Institute Johnson University

About

Sara Pressel is an author at The University of Texas Health Science Center at Houston specializing in medicine, hypertension, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	2.7K
2	Public Health	12	12	1K
3	Health Sciences	3	3	582
4	Clinical Nutrition	2	2	420
5	Diabetes	2	2	389

Sara Pressel

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
PREDIAGNOSTIC SERUM SELENIUM AND RISK OF CANCER WalterC Willett, J. Steven Morris, Sara Pressel, The Lancet Cancer RiskSelenium DeficiencyMedicinePathologyCancer Prevention	1983	552
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial Russell E. Ware, Barry R. Davis, William H. Schultz, The Lancet Pediatric HematologyHematologyNeurological MonitoringSickle CellHemostasis	2015	496
Relation of Serum Vitamins a and E and Carotenoids to the Risk of Cancer Walter C. Willett, B. Frank Polk, Barbara A. Underwood, New England Journal of Medicine NutritionChemoprevention StrategyEpidemiology Of CancerPathologyOxidative Stress	1984	358
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes John B. Kostis, Alan C. Wilson, Ronald S. Freudenberger, The American Journal of Cardiology HypertensionUrologyLong-term EffectDiabetes ManagementCardiovascular Disease	2004	328
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Jackson T. Wright, William C. Cushman, Barry R. Davis, Controlled Clinical Trials HypertensionLipid-lowering TreatmentHealth PolicyCardiovascular DiseaseAntihypertensive Therapy	2001	311
Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease Paul Muntner, Barry R. Davis, William C. Cushman, Hypertension HypertensionHeart FailureCardiovascular PharmacologyPharmacotherapyPreventive Cardiology	2014	221
Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults Benjamin H. Han, David Sutin, Jeff D. Williamson, JAMA Internal Medicine	2017	180
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus Gijs F. N. Berkelmans, Soffia Guðbjörnsdóttir, Frank L.J. Visseren, European Heart Journal	2018	86
Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Mahboob Rahman, Charles Baimbridge, Barry R. Davis, American Journal of Kidney Diseases Metabolic SyndromeHypertensionUrologyRenal DiseaseRenal Function	2008	82
Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival John B. Kostis, Javier Cabrera, Jerry Cheng, JAMA	2011	80

Page 1